Adagene is a technology company.
Adagene is a technology company.
Adagene has raised $119.0M across 2 funding rounds.
Adagene has raised $119.0M in total across 2 funding rounds.
Adagene has raised $119.0M in total across 2 funding rounds.
Adagene's investors include Base Partners, DST Global, General Atlantic, Carmen Chang, Hans Tung, Paradigm, Sequoia Capital China.
Adagene is a Nasdaq-listed (ADAG), clinical-stage biotechnology company focused on developing monoclonal antibody drugs for cancer treatment, primarily in China.[1][2] It builds advanced immunotherapy products using proprietary platforms like NEObody™, SAFEbody®, and POWERbody™, which leverage computational biology and AI to create antibodies with novel mechanisms of action (MOAs) that enhance efficacy and safety in the tumor microenvironment (TME).[1] Key assets include ADG126 (masked anti-CTLA-4 SAFEbody® in Phase 1b/2 for cancer), ADG116 (anti-CTLA-4 in Phase 1b/2 for solid tumors), ADG106 (CD137 agonist), and others like ADG206, ADG104 (anti-PD-L1 in Phase 2), and ADG125 (anti-CSF-1R in Phase 2).[1][2] These serve oncology patients and partners, solving problems of toxicity and limited efficacy in existing immunotherapies by targeting unique epitopes and enabling precision activation.[1] Despite low revenue ($103k TTM) and losses ($29.89m), it maintains strong financial health and global partnerships.[2]
Founded and led by world-class experts in antibody discovery and engineering, Adagene emerged to tackle unmet needs in cancer immunotherapy where prior treatments failed.[1] Its backstory centers on pioneering dynamic precision antibody technologies, starting with the Dynamic Precision Library discovery engine that integrates AI and computational biology for rational antibody design.[1] Early traction came from building a pipeline of "first or best in class" assets and securing partnerships with global firms for applications like precision-guided antibody-drug conjugates.[1] As a clinical-stage player, pivotal moments include advancing multiple programs into Phase 1b/2 and Phase 2 trials, positioning it as a Nasdaq-listed innovator.[1][2]
Adagene stands out through its Dynamic Precision Antibody Technology platform, which addresses key immunotherapy challenges:
This tech-driven approach differentiates it from traditional antibody developers.[1]
Adagene rides the precision oncology wave, capitalizing on AI and computational tools to revolutionize antibody design amid rising demand for safer, more effective cancer immunotherapies.[1] Timing aligns with surging interest in novel MOAs like CTLA-4 and PD-L1 targets, where market forces favor bispecifics, masked antibodies, and TME-activated drugs to improve response rates beyond checkpoint inhibitors.[1][2] Its China-based operations tap into Asia's biotech boom, while Nasdaq listing and global ties amplify influence; it shapes the ecosystem by licensing tech for antibody-drug conjugates and inspiring AI-biology convergence in drug discovery.[1]
Adagene's pipeline momentum, with multiple Phase 2 assets and strong financial health, positions it for potential breakthroughs in solid tumor treatments.[2] Next steps likely include trial readouts (e.g., ADG126, ADG116) and partnership expansions, fueled by AI advancements in protein engineering.[1] Trends like TME-targeted therapies and combo regimens will propel growth, evolving its role from innovator to ecosystem leader—echoing its mission to redefine antibodies and bring hope to cancer patients.[1]
Adagene has raised $119.0M across 2 funding rounds. Most recently, it raised $69.0M Series D in January 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2020 | $69.0M Series D | Base Partners, DST Global, General Atlantic, Carmen Chang, Hans Tung, Paradigm, Sequoia Capital China | |
| Mar 1, 2018 | $50.0M Series C | Base Partners, DST Global, Carmen Chang, Hans Tung, Paradigm, Sequoia Capital China |